Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Investing Activities: 2012-2025

Historic Cash from Investing Activities for Aytu Biopharma (AYTU) over the last 14 years, with Jun 2025 value amounting to -$2.6 million.

  • Aytu Biopharma's Cash from Investing Activities fell 8773.53% to -$3.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.6 million, marking a year-over-year decrease of 678.12%. This contributed to the annual value of -$2.6 million for FY2025, which is 678.12% down from last year.
  • Per Aytu Biopharma's latest filing, its Cash from Investing Activities stood at -$2.6 million for FY2025, which was down 678.12% from -$329,000 recorded in FY2024.
  • In the past 5 years, Aytu Biopharma's Cash from Investing Activities ranged from a high of -$117,000 in FY2023 and a low of -$3.2 million during FY2022.
  • For the 3-year period, Aytu Biopharma's Cash from Investing Activities averaged around -$1.0 million, with its median value being -$329,000 (2024).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first skyrocketed by 96.40% in 2023, then slumped by 678.12% in 2025.
  • Yearly analysis of 5 years shows Aytu Biopharma's Cash from Investing Activities stood at -$2.8 million in 2021, then decreased by 16.75% to -$3.2 million in 2022, then soared by 96.40% to -$117,000 in 2023, then slumped by 181.20% to -$329,000 in 2024, then crashed by 678.12% to -$2.6 million in 2025.